84400-99-7

Basic information

• Product Name: 7-CHLOROFURO[2,3-C]PYRIDINE
• Synonyms: 7-CHLOROFURO[2,3-C]PYRIDINE
• CAS NO: 84400-99-7
• Molecular Formula: C₇H₄ClNO
• Molecular Weight: 153.57
• Mol File: 84400-99-7.mol
• Article Data: 12

Chemical Properties

• Melting Point: 64-65.5 °C
• Boiling Point: 242.806 °C at 760 mmHg
• Flash Point: 100.646 °C
• Appearance: /
• Density: 1.377 g/cm³
• Vapor Pressure: 0.052mmHg at 25°C
• Refractive Index: 1.624
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.88±0.30(Predicted)
• CAS DataBase Reference: 7-CHLOROFURO[2,3-C]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-CHLOROFURO[2,3-C]PYRIDINE(84400-99-7)
• EPA Substance Registry System: 7-CHLOROFURO[2,3-C]PYRIDINE(84400-99-7)

Safety Data

• Hazardous Substances Data: 84400-99-7(Hazardous Substances Data)

Usage

General Description

7-Chlorofuro[2,3-c]pyridine, also known as 7-chloro-2,3-dihydro-6H-furo[2,3-c]pyridine, is a chemical compound with the molecular formula C6H4ClNO. It is a heterocyclic compound that belongs to the furo[2,3-c]pyridine family. This chemical features a chlorine atom attached to a furo[2,3-c]pyridine ring, making it a halogenated furo[2,3-c]pyridine derivative. It has potential applications in the development of pharmaceuticals and agrochemicals due to its unique structural properties. Additionally, it may also be used as an intermediate in organic synthesis for the preparation of other heterocyclic compounds. As with any chemical compound, proper handling and safety precautions should be observed when working with 7-chlorofuro[2,3-c]pyridine.

InChI:InChI=1/C7H4ClNO/c8-7-6-5(1-3-9-7)2-4-10-6/h1-4H

Upstream product

• 84400-98-6 furo<2,3-c>pyridin-7(6H)-one 
• 1066-54-2 trimethylsilylacetylene 
• 39244-10-5 (E)-3-furan-3-yl-acrylic acid 
• 539-47-9 3-(fur-2-yl)crotonic acid 
• 26956-43-4 5H-furo[3,2-c]pyridin-4-one 
• 119924-26-4 (E)-3-(2-furanyl)-2-propenoyl azide 
• 19539-50-5 furo<2,3-c>pyridine 
• 1219102-03-0 7-chloro-2-trimethylsilylfuro[2,3-c]pyridine 
• 181526-20-5 Furo[2,3-c]pyridine 6-oxide 

Downstream Products

• 19539-50-5 furo<2,3-c>pyridine 
• 117612-53-0 7-methoxyfuro[2,3-c]pyridine 
• 86518-10-7 acetyl-2 chloro-4 furo<3,2-c>pyridine 
• 1613479-45-0 C₁₃H₇F₂NO₂ 
• 112372-06-2 furo<2,3-c>pyridine-2-carboxaldehyde 
• 153863-91-3 2-aminomethylfuro<2,3-c>pyridine 
• 252029-87-1 2-(1-tert-butoxycarbonyl-4-methoxy-piperidin-4-yl)-7-methoxy-furo[2,3-c]pyridine-4-carboxylic acid 4-nitro-phenyl ester 
• 252029-83-7 7-methoxy-2-(tetrahydro-pyran-4-yl)-furo[2,3-c]pyridine-4-carboxylic acid 4-nitro-phenyl ester 
• 252029-86-0 7-methoxy-2-(tetrahydrofuran-3-yl)furo[2,3-c]pyridine-4-carboxylic acid 4-nitrophenyl ester 
• 252029-85-9 7-methoxy-2-pyridin-3-yl-furo[2,3-c]pyridine-4-carboxylic acid 4-nitrophenyl ester 
• 252029-84-8 7-methoxy-2-methoxymethylfuro[2,3-c]pyridine-4-carboxylic acid 4-nitrophenyl ester 
• 252029-82-6 2-ethyl-7-methoxyfuro[2,3-c]pyridine-4-carboxylic acid 4-nitrophenyl ester 

Relevant articles and documents

HETEROCYCLIC SULFONAMIDE DERIVATIVE AND MEDICINE COMPRISING SAME

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.

Discovery and optimization of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1

The discovery and potency optimization of a series of 7-aminofuro[2,3-c] pyridine inhibitors of TAK1 is described. Micromolar hits taken from high-throughput screening were optimized for biochemical and cellular mechanistic potency to ～10 nM, as exemplified by compound 12az. Application of structure-based drug design aided by co-crystal structures of TAK1 with inhibitors significantly shortened the number of iterations required for the optimization.

7-AMINOFUROPYRIDINE DERIVATIVES

Compounds of Formula 1, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.